Publicaciones (24) Publicaciones de ERNESTO PÉREZ PERSONA

2024

  1. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

  2. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2023

  1. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

    Hematology (United Kingdom), Vol. 28, Núm. 1

  2. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 10, pp. e341-e347

2022

  1. Treatment burden in multiple myeloma according to comorbidity in real life

    Annals of Hematology

  2. Urgent and unexpected findings in oncology and hematology patients: a practical approach to imaging

    Radiologia, Vol. 64, Núm. 5, pp. 464-472

  3. Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma

    European Journal of Haematology

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  3. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  4. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

  5. Primary plasma cell leukaemia presenting with flower-shaped nuclei

    British Journal of Haematology

  6. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999

  7. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

    Annals of Hematology, Vol. 100, Núm. 7, pp. 1769-1778

2020

  1. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 661-673

2017

  1. Further psychometric validation of the GAH scale: Responsiveness and effect size

    Journal of Geriatric Oncology, Vol. 8, Núm. 3, pp. 211-215

2015

  1. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale

    Journal of Geriatric Oncology, Vol. 6, Núm. 5, pp. 353-361

2014

  1. Independencia transfusional en un paciente con anemia refractaria con exceso de blastos tipo 2 refractario a 5-azacitidina tratado con deferasirox y agentes estimuladores de colonias

    Medicina Clinica

  2. Pylephlebitis: Incidence and prognosis in a tertiary hospital

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 6, pp. 350-354

2010

  1. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: Comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

    British Journal of Haematology, Vol. 148, Núm. 1, pp. 110-114